SEC Form 4 · accession 0001915598-26-000004
Dyne Therapeutics, Inc. · DYN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Johanna Friedl-Naderer
Officer — Chief Commercial Officer
Period of report
Aug 13, 2026
Accepted (ET)
Aug 17, 2026 · 4:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001818794
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 13, 2026 | S | 226 | $26.28 | D | 153,982 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
- F3Includes 119,928 unvested RSUs.